Literature DB >> 25229989

Intravenous glucagon in a deliberate insulin overdose in an adolescent with type 1 diabetes mellitus.

Mary White1, Margaret R Zacharin1, George A Werther1, Fergus J Cameron1.   

Abstract

Massive insulin overdose may be associated with unpredictable and prolonged hypoglycemia. Concerns surrounding the potential provocation of insulin release from beta cells have previously prevented the use of intravenous glucagon as an adjunct to infusion of dextrose in this situation. We describe the case of a 15-yr-old boy with type 1 diabetes mellitus (T1DM) who presented with profound hypoglycemia following an overdose of an unknown quantity of premixed insulin. Owing to an increasing dextrose requirement and a dependence on hourly intramuscular glucagon injections, a continuous intravenous infusion of glucagon was commenced which successfully avoided the requirement for central venous access or concentrated dextrose infusion. Nausea was managed with anti-emetics. Intramuscular and subcutaneous glucagon is effective in the management of refractory and severe hypoglycemia in youth with both T1DM and hyperinsulinism. Concerns regarding the precipitation of rebound hypoglycemia with the use of intravenous glucagon do not relate to those with T1DM. This treatment option may be a useful adjunct in the management of insulin overdose in youth with T1DM and may avoid the requirement for invasive central venous access placement.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  attempted suicide; drug overdose; hypoglycemia; intravenous glucagon; type 1 diabetes mellitus

Mesh:

Substances:

Year:  2014        PMID: 25229989     DOI: 10.1111/pedi.12210

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  4 in total

Review 1.  Factitious hypoglycemia in children and adolescents with diabetes.

Authors:  Viviana Bauman; Adaya C Sturkey; Rosa Sherafat-Kazemzadeh; Jennifer McEwan; Paul M Jones; Ashley Keating; Elvira Isganaitis; Alyne Ricker; Kristina I Rother
Journal:  Pediatr Diabetes       Date:  2018-02-21       Impact factor: 4.866

2.  Peripheral IV Insulin Infusion Infiltration Presenting as "Insulin Resistance".

Authors:  Tiffany Y Kim; Kenneth A Woeber; Heidimarie Windham MacMaster; Robert J Rushakoff
Journal:  Crit Care Med       Date:  2016-11       Impact factor: 7.598

Review 3.  Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange.

Authors:  Gina Agiostratidou; Henry Anhalt; Dana Ball; Lawrence Blonde; Evgenia Gourgari; Karen N Harriman; Aaron J Kowalski; Paul Madden; Alicia H McAuliffe-Fogarty; Molly McElwee-Malloy; Anne Peters; Sripriya Raman; Kent Reifschneider; Karen Rubin; Stuart A Weinzimer
Journal:  Diabetes Care       Date:  2017-12       Impact factor: 19.112

4.  Intraperitoneal, subcutaneous and intravenous glucagon delivery and subsequent glucose response in rats: a randomized controlled crossover trial.

Authors:  Ilze Dirnena-Fusini; Marte Kierulf Åm; Anders Lyngvi Fougner; Sven Magnus Carlsen; Sverre Christian Christiansen
Journal:  BMJ Open Diabetes Res Care       Date:  2018-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.